Preliminary results from the DIRECT-II Study: a prospective, randomized, active-control, multi-center, non-inferiority study comparing the safety and efficacy of the Svelte drug-eluting coronary stent IDS to the Medtronic Vascular (Santa Rosa, CA) Resolute IntegrityTM DES Hospital Oost Limburg, Genk, Limburg
TCT-197
The Svelte Drug-eluting Stent and Integrated Delivery System: 12 Month Results of the DIRECT I First-in-man Study Background: The Svelte (New Providence, NJ) drug-eluting stent combines sirolimus with a novel, amino acid-based fully bioabsorbable drug carrier. The stent is mounted on an Integrated Delivery System (IDS) consisting of a low compliant balloon with balloon control bands enveloping the balloon edges and affixed to a 0.014" wire, providing a very low profile, flexible, drug-eluting coronary stent system specifically designed for direct stenting. The DIRECT I first-in-man study was designed to evaluate the feasibility of the Svelte drug-eluting stent IDS. Methods: 30 patients with a de novo lesion in a native coronary artery, with a reference vessel diameter between 2.5 mm and 3.5 mm and lesion length < 23 mm, were assessed. Patients with successful, uncomplicated treatment of one additional lesion in a non-target vessel were also included. All patients completed 6-month QCA and IVUS (+ OCT in a subset) and are followed clinically for 5-years. The study primary endpoints were target vessel failure and angiographic late lumen loss at 6-months. Results: At 6 months, no patient had suffered a clinically-driven MACE, there was 2.7% stent volume obstruction (via IVUS) and stent strut coverage was 98% (via OCT). There were no adverse clinical results between 6 and 12 months, indicating no evidence of late catch-up. Full independent core lab and DSMB-adjudicated baseline and 6 month QCA, IVUS and OCT data, and clinical outcomes to 12-months will be reported. Conclusions: The Svelte sirolimus-eluting coronary stent IDS, utilizing an antiinflammatory, naturally-occurring amino acid-based drug carrier, demonstrated excellent clinical outcomes, low neointimal proliferation, and uniform vessel healing at 6-months. The clinical benefit was sustained in all patients through 12-months. DIRECT II, a prospective, randomized, active-control, multi-center, non-inferiority study is currently underway. Miyazaki medical association hospital, Miyazaki, Japan Background: In many reports, SES is more effective in decreasing late lumen loss and restenosis rate than BMS. However, long-term follow-up results of SES remain unclear. We sometimes experience late restenosis cases in SES implanted lesion. Methods: We tried angiographic follow-up every year of the patients SES implanted. We could follow 60 lesions completely and evaluated MLD of those lesions in each year. We ruled out revascularised lesions. We sometimes experience late restenosis cases in SES implanted lesion. Results: We implanted SES in 3972 lesions in the heart center from April 2004 to August 2012. We studied consecutive 58 lesions we could follow up every year. We estimated the changes of MLD of these 58 lesions. During 1 to 2-year follow-up, there is not remarkable change in MLD (1-year: 2.62AE0.55, 2-year: 2.49AE0.56). But at 3-year follow-up, MLD got smaller remarkably (3-year:2.29AE0.65). After that there is not remarkable change (4-year: 2.30AE0.70, 5-year:2.26AE0.74, 6-year:2.21AE0.58). 7.4% of 3-year follow-up patients, 5.5% of 4-year follow-up patients and 7.5% of 5-year follow-up patients are ruled out by revascularization.
Conclusions: MLD of SES implanted lesions get smaller. The extent of lumen loss was large after 3 years of PCI. We have to follow up SES implanted patients carefully and continuously because of late stent thrombosis and late restenosis. But this result suggest that late restenosis becomes less common in 4 years or later after SES implanted.
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Safety and efficacy of a novel drug-eluting stent with a bioresorbable polymer in a real life cohort Background: A novel sirolimus-eluting stent with a bioabsorbable polymer (Osiro, Biotronik, Germany) is now available. The safety and efficacy of this drug-eluting stent (DES) in an all comers setting is unknown. Methods: Between June 2011 and January 2013, 234 patients were treated with the Osiro (Biotronik, Germany) stent. Indication for the Osiro (Biotronik, Germany) was left to the operator discretion. Demographic, clinical and procedural characteristics were collected through institutional and catheterization databases review. Short and long-term clinical follow-up were available through institutional database review and telephone contact. Results: The mean age was 65AE10 years with a predominance of male (76%). They had hypertension in 70% and diabetes in 35% of cases. Coronary artery disease was already known in most patients as 47% had a previous percutaneous coronary intervention 40% had a myocardial infarction (MI) and 18% had previous coronary artery bypass surgery. Clinical presentation was acute coronary syndrome in 77% of patients. Mean reference diameter was 2.8AE0.5mm, lesion length was 22AE15 mm and lesion stenosis was 80AE13%. The mean used stent diameter and length were 2.8AE0.4mm and 22AE6mm respectively. Osiro stent was used to treat bifurcation lesion in 34% and thrombus-containing lesion in 11%. Procedural and technical TUESDAY, OCTOBER 29, 2013 Background: Long term safety and efficacy of the Elixir DESyneÒ BD Novolimus Eluting Coronary Stent System (NECSS), a Co-Cr stent with a bioabsorbable polymer compared to the control Endeavor Zotarolimus Eluting Coronary Stent System is not known Methods: 149 patients were randomized 3:1, either to the Elixir DESyne BD Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the Endeavor Zotarolimus-eluting CSS (ZECSS) loaded with 10mcg per mm of stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were analyzed for the primary endpoint of in-stent late lumen loss (LLL) assessed by qualitative coronary angiography (QCA) at 6 months. Moreover, all patients underwent evaluation for the secondary endpoints including the Deviceorientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for angiographic endpoints at 6 months including: in-segment LLL, percent diameter stenosis, minimal lumen diameter post-procedure, and angiographic binary restenosis (ABR) (!50%). A subset of patients underwent intravascular ultrasound (IVUS) evaluation including percent (%) neointimal obstruction at 6 months. Results: The study met the primary endpoint demonstrating both non-inferiority and superiority of the DESyne BD compared to the control (0.12AE0.15 vs 0.67AE0.47, p<0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs 7.9%, p¼0.003). Excellent clinical results at 6 months were demonstrated for both devices (DoCE 2.7% vs. 3.2%, p¼ 1.00). Sustained low clinical event rates were observed at 12 months and 24 months (DoCE 2.7% vs 3.2% p¼1.0) Conclusions: The DESyne BD NECSS demonstrated sequential non-inferiority and superiority over a durable polymer Endeavor ZECSS for in-stent late lumen loss at 6 months. Clinical events remained low through 24 months suggesting long term safety.
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The middle-term outcome of small-vessel stenting with the second-generation drug-eluting stents.
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